Lantern’s Core Operational Strength
Technology and Data Driven.
Lantern Pharma is reinventing the cancer drug development process by tailoring multiple promising precision drug programs to the right cancer patients using advanced genomics and artificial intelligence (AI) with significantly reduced cost and time. Lantern has in-licensed, validated, de-risked clinical stage drugs that are discontinued for development. Lantern identifies genetic signatures or molecular markers for the patient response to the drug and further validates by conducting small, focused phase 2 clinical trials to greatly increase the value of each drug, thereby creating multiple exit points for each drug.
RADR V 3.0™ – Integrated Data Analytics, Experimental Biology and Machine Learning based Platform for Patient Genetic Profiling for Drug Response Prediction.
Meet Our Team
Strong scientific and business team with expertise in pharmaceutical development.